Kentera

Oxybutynin, the active ingredient in Kentera, is an antimuscarinic presented as a transdermal patch for cutaneous, transdermal use. It reduces detrusor overactivity and is indicated for the management of overactive bladder, urge urinary incontinence, and urinary urgency and frequency in adult patients.

GNH USA supplies Kentera as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing consistent quality for EU‑market products. The company adheres to stringent regulatory standards and offers reliable logistics for global distribution, ensuring timely delivery to end‑users.

Oxybutynin is an antimuscarinic used to manage symptoms of overactive bladder and related urinary disorders.

- Overactive bladder: reduces urinary frequency and urgency, improving bladder control. - Urge urinary incontinence: decreases involuntary leakage episodes. - Urinary urgency and frequency: alleviates sudden urges and high voiding frequency.

Oxybutynin may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Dry mouth: reduced salivary flow causing thirst. - Constipation: slowed gastrointestinal motility leading to hard stools. - Blurred vision: difficulty focusing due to ocular anticholinergic effect. - Skin irritation: redness, itching or rash at the patch site.

Serious or Rare Side Effects: - Severe allergic reaction: rash, swelling, or anaphylaxis. - Urinary retention: difficulty initiating or completing urination. - Cardiac arrhythmia: irregular heartbeat or tachycardia. - Hepatic dysfunction: elevated liver enzymes or hepatitis.

When prescribing or using Kentera, consider the following precautions.

- Assess renal and hepatic function: adjust use in patients with impairment. - Avoid in narrow‑angle glaucoma: risk of increased intra‑ocular pressure. - Monitor for urinary retention: especially in elderly patients. - Caution in cardiac disease: possible tachycardia or arrhythmia. - Do not apply to broken skin: may increase systemic absorption. - Store at room temperature: keep patch in original packaging, protect from moisture and heat.

Oxybutynin can interact with several drug classes; awareness helps prevent adverse outcomes.

Major Interactions (Avoid): - Potent CYP3A4 inhibitors: may increase oxybutynin plasma levels. - Other anticholinergic agents: additive anticholinergic effects. - Beta‑blockers: may exacerbate cardiac side effects.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers: may reduce therapeutic efficacy. - Diuretics: may increase risk of urinary retention. - Alcohol: may enhance dizziness and central nervous system effects.